Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma.
In connection with this announcement, a conference call was organized on May 23, 2008.
The slideshow is available here:
| PR in english | 120.39 KB |
| CP en français | 123.6 KB |